Last reviewed · How we verify

NCT05994768: OEN

18F-FDG Tomography and Labeled Leukocyte Scintigraphy

Completed Last updated 30 November 2023
What this trial tests

trial testing 18F-FDG PET/CT in Malignant Otitis Externa in 18 participants. Completed in 18 October 2023.

Timeline
18 December 2020
Primary endpoint
12 July 2023
18 October 2023

Quick facts

Lead sponsorCentral Hospital, Nancy, France
StatusCompleted
Study typeOBSERVATIONAL
Enrollment18
Start date18 December 2020
Primary completion12 July 2023
Estimated completion18 October 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Central Hospital, Nancy, France

Who can join

Adults 18 to 80, any sex, with Malignant Otitis Externa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will aim to show that there is a superiority of 18F-FDG PET/CT compared to labeled leukocyte scintigraphy in patients with a malignant otitis externa.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of 18F-FDG PET/CT

Trials testing the same drug.

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05994768.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing